# AMELI-01 (NCT03190278)

> Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

No report yet. It can be ordered.

- Drugs tested: UCART123v1.2
- Indication: relapsed/refractory acute myeloid leukemia

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03190278
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Cellectis S.A.
- Conditions: Relapsed/Refractory Acute Myeloid Leukemia
- Interventions: UCART123v1.2
- Enrollment: 29
- Primary outcome: Incidence of adverse events (AE)/serious adverse events (SAE)/Dose Limiting Toxicities (DLT) [Safety and Tolerability]
- Primary outcome: Dose escalation and expansion part: Occurrence of DLTs

## Indexed commentary on AMELI-01 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 2
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=ameli-01-nct03190278